Sun Pharmaceutical Industries Ltd. sees a credit rating action

Sun Pharma has secured USD 12 billion of committed acquisition financing for the Organon transaction, structured initially as a bridge loan. This is higher than Organon’s USD 11.75 billion enterprise value and is intended to be refinanced later through term loans and capital-market funding. ^[1]

The leverage impact is significant:

• Pre-acquisition: Sun Pharma was in a net-cash position, having maintained that position for more than a decade; therefore, its net debt-to-EBITDA ratio was not a positive leverage multiple. ^[2]
• Post-acquisition: Moody’s estimates net debt-to-EBITDA at approximately 2.3x pro forma at March 2027. ^[1]
• S&P’s related measure: adjusted debt-to-EBITDA is projected at 1.8x in FY2028, declining toward 1.5x over the following year as cash flow supports deleveraging. ^[3]

Implication: the financing shifts Sun from net cash to approximately 2.3x net leverage immediately after completion—a material balance-sheet change, although the agencies view it as temporary if integration proceeds smoothly and the company uses its expected cash generation to reduce debt.

The reports do not identify a specific financial maintenance covenant applicable to Sun Pharma’s own borrowings. S&P explicitly says Sun has no financial covenants on its borrowings; the rating agencies instead highlighted leverage, liquidity and financial-policy thresholds as rating-maintenance tests. Organon is expected to retain sufficient headroom under its applicable financial covenants after completion. ^[3]

Rating-sensitive financial tests

• Moody’s gross leverage: The key threshold is Moody’s-adjusted gross debt/EBITDA. Post-acquisition leverage is expected to peak at approximately 3.0x and decline toward 2.0x within 18 months. Moody’s indicated positive rating momentum if gross leverage improves below 2.0x alongside excellent liquidity, while leverage remaining above 3.0x after synergies and debt reduction would create downgrade pressure. ^[4]
• S&P debt reduction: S&P’s stable outlook assumes its adjusted debt/EBITDA ratio falls to approximately 1.5x within 24 months of the acquisition. A downgrade could follow if leverage rises and remains above 2.0x on a sustained basis. An upgrade scenario would require leverage moving toward 1.0x sustainably, together with successful integration and cash-flow generation. ^[5]
• Liquidity coverage: Moody’s expects liquidity sources to cover uses by approximately 1.3x over the 12 months to 31 March 2027, with liquidity still exceeding uses even if EBITDA declines by 15%. This is a rating-assumption stress test rather than a disclosed contractual covenant. ^[3]
• Capital-allocation discipline: The stable outlook assumes Sun avoids another transformational debt-funded acquisition during the Organon integration period, maintains conservative shareholder distributions and prioritizes debt reduction. A shift toward more aggressive acquisitions or distributions could pressure the ratings even if reported leverage remains within the base case. ^[1]

Bottom line: the practical “maintenance tests” are rapid post-deal deleveraging, leverage staying below the agencies’ stress thresholds, adequate liquidity under an EBITDA shock, and conservative capital allocation. The reports do not present these as lender-imposed maintenance covenants for Sun; they are rating-agency downside and upgrade thresholds.

Verdict: The Organon financing is structurally much larger and initially shorter-dated than Sun Pharma’s existing reported debt, but the available disclosures do not provide a coupon, credit spread, all-in interest cost, bridge tenor, or final amortisation schedule. Accordingly, there is no defensible basis to conclude that the acquisition debt will be cheaper or more expensive than Sun’s legacy international obligations or peer acquisition debt.

Sun Pharma: proposed financing versus existing debt

• Sun has secured a USUSD 12 billion committed acquisition bridge for the Organon transaction. It is working with lenders to replace that bridge after closing with a mix of term loans and capital-market financing. The bridge’s margin, fees and final maturity have not been disclosed. ^[1]
• Sun’s proposed long-term financing is expected to benefit from investment-grade credit ratings: Moody’s Baa1 and S&P Global’s BBB+, both with stable outlooks. These ratings indicate access to investment-grade markets, but do not establish the actual borrowing cost. ^[6]
• Earlier market reporting discussed a possible euro-denominated bond and USUSD 3-4 billion of offshore loans; the euro bond was reported as potentially carrying a rating one to two notches above Organon’s pre-transaction rating. These were financing options under consideration, not confirmed pricing terms. ^[7]
• Sun’s latest consolidated debt position was relatively modest: total debt of Rs 4,081.6 Crores in Q1 FY27, including Rs 4,050.3 Crores of current borrowings and Rs 31.26 Crores of non-current borrowings. Consolidated net debt was negative Rs 5,688.9 Crores, indicating a net-cash position. ^{[8] [9] [10] [11]}
• Existing debt-servicing capacity was strong, with consolidated interest coverage of 51.58x in Q1 FY27. However, neither a weighted-average interest rate nor an international-debt maturity schedule is reported, so the existing debt cannot be compared directly with the proposed bridge on a coupon or tenor basis. ^[12]

Peer acquisition-financing benchmark

What the comparison implies

• Maturity: Torrent’s disclosed precedent is a staggered 2-to-5-year bond ladder. Sun’s bridge is temporarily short-dated by design, but the eventual term-loan or bond maturity profile is still unknown. It could ultimately resemble a multi-year ladder, but that has not been committed publicly.
• Cost: There is no disclosed rate benchmark for either transaction. The relevant comparison should ultimately be Sun’s all-in takeout cost—including margin, upfront and commitment fees, hedging and refinancing costs—against Torrent’s bond coupons. Those peer coupons were also not reported.
• Credit risk: Sun begins from a net-cash balance sheet, but the acquisition is expected to raise adjusted leverage materially: Moody’s estimates gross debt/EBITDA at around 3.0x immediately after completion, with a reduction toward 2.0x within 18 months. ^[1] The financing cost will therefore matter less than the final refinancing mix, the duration of the bridge and the pace of deleveraging.
• Bottom line: The evidence supports a comparison of structure, not of actual funding cost. Sun has stronger disclosed credit access than Organon standalone, while Torrent provides the clearest Indian-pharma maturity precedent; neither source set provides the coupon or spread needed for a true cost-of-debt ranking.